Valitor Bio Appoints Experienced Biotech And Ophthalmic Executive Gregory D. Kunst As Chief Executive Officer

Valitor, a biotechnology company focused on developing next-generation ophthalmic medicines, has announced the appointment of Gregory D. Kunst as its chief executive officer and member of the board of directors. Mr. Kunst succeeds interim CEO Michael Ostrach and brings a wealth of experience across the ophthalmic field, including drugs, medical devices, drug delivery systems, diagnostics, biotechnology, pharmaceuticals, and cell and gene therapy products. His extensive expertise also covers global corporate development, strategic planning, clinical development, regulatory affairs, health policy, marketing, commercialization, business development, market access, and medical affairs.

Anthony Aiudi, chairman of Valitor’s board of directors and representative of lead investor Morningside, said that the company is thrilled to welcome Mr. Kunst at this pivotal stage of growth. He highlighted that Mr. Kunst’s achievements and diverse experience in ophthalmology make him well-positioned to accelerate the company’s progress into clinical and commercial stages. Aiudi emphasized that under Mr. Kunst’s leadership, Valitor aims to advance VLTR-559, its long-acting anti-VEGF therapy for wet age-related macular degeneration, into clinical trials and continue pioneering new ophthalmic treatments using its multivalent biopolymer platform technology.

Gregory D. Kunst expressed enthusiasm about joining Valitor, noting that the company’s science, technology, and mission are uniquely positioned to deliver meaningful advancements in ophthalmology. He highlighted the broad potential of the multivalent biopolymer platform to transform the treatment of vision-threatening diseases. Mr. Kunst also emphasized his commitment to working closely with the Valitor team to drive clinical development and build a robust pipeline of therapies that can improve patient outcomes.